News

Article

Texas ophthalmologist facing fraud, money laundering charges

Author(s):

According to the United States Attorney’s Office Southern District of Texas, Michael Hochman, MD, is set to be arraigned Oct. 12 before U.S. Magistrate Judge Christopher dos Santos.

(Image Credit: AdobeStock/dianaduda)

(Image Credit: AdobeStock/dianaduda)

Texas ophthalmologist Michael Hochman, MD, has been indicted by the United States Attorney’s Office Southern District of Texas on charges of health care fraud and money laundering.

The indictment was announced by US Attorney Alamdar S Hamdani in a news release.

A federal grand jury handed down the 5-count indictment on September 27, and Hochman made his initial court appearance on October 5. An arraignment is set for October 12 before US Magistrate Judge Christopher dos Santos.

According to court documents, Hochman is an ophthalmologist who owned and operated Michael A Hochman PA and Laredo Laser and Surgery Ltd. in Laredo, Texas.

According to the US Attorney’s Office, Southern District of Texas, Hochman allegedly falsely diagnosed vulnerable patients with ophthalmological diseases and various degenerative eye conditions. According to court documents, he allegedly directed optometry staff to conduct fraudulent, repetitive and excessive medical procedures on patients to maximize profits.

The indictment also alleges that through his actions, Hochman caused Medicare and other health care benefit programs to remit payment for millions of dollars in proceeds into various corporate and personal bank accounts.

The US Attorney’s Office asserts the false and fraudulent claims allegedly made by Hochman to Medicare, Medicaid and Tricare totaled $402,536,174. As a result of the false and fraudulent claims, Medicare, Medicaid and Tricare paid approximately $13,317,914, according to the charges.

Moreover, according to the US Attorney’s Office the indictment alleges Hochman used the money from the fraud scheme to buy luxury vehicles, airplanes, antique furniture, coins and other merchandise.

If convicted, Hochman could face up to 10 years in prison for one count of health care fraud. He also faces four counts of money laundering, with a potential a penalty of up to 20 years imprisonment. All charges also carry a possible $250,000 maximum fine.

Assistant US Attorneys Tina Ansari, Cynthia Villanueva, Tyler White and Grace Murphy are prosecuting the case, according to the US Attorney’s Office.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.